INTRODUCTION
Premature infants, especially those born before 30 weeks' gestation, often experience periods lasting from days to weeks in which circulating thyroid hormones are at very low levels. 1 In this syndrome of transient hypothyroxinemia of prematurity (THOP), TSH is usually normal and circulating thyroxine levels eventually rise to age-appropriate levels. These transiently low levels of thyroid hormones have been shown to be either markers or causes of substantially increased risks of neurodevelopmental disability in three large studies. 2 -5 However, it is not yet known whether treatment with thyroid hormone during this period of hypothyroxinemia improves neurodevelopmental outcome. A few small trials have been undertaken to examine this question, but results are mixed, and no published trial has had sufficient power to properly test the hypothesis. In light of the uncertainty surrounding this issue, we undertook a survey of neonatologists to examine the extent of variation in current practice. Most endocrinologists do not currently recommend treating THOP with thyroid hormones. 6 
METHODS
We obtained a computer-generated random sample of 100 neonatologists from the US directory of neonatologists. 7 We first randomly sampled 100 pages from this 301-page directory, and then randomly sampled one neonatologist from each page. For each neonatologist we recorded mailing address and e-mail. In July 2001, we mailed a seven-item questionnaire about THOP treatment to the 100 sampled neonatologists (Figure 1 ). The definition of THOP used in the questionnaire was ''the drop in total T4 commonly detected by thyroid screening programs in premature infants, which is usually unaccompanied by any abnormality in TSH, and which generally returns to normal after several days or weeks.'' If no response was received in 3 weeks, we e-mailed the questionnaire to the sampled neonatologist, and if no response was received in 2 weeks after that, we e-mailed the questionnaire a second time. Eight surveys were returned because either the regular mail or e-mail address was no longer correct. Of the 92 neonatologists successfully contacted, 63 (68.5%) returned the survey. One neonatologist returned, but did not complete, the survey, stating that he no longer practiced neonatology. The analysis is based on the remaining 62 surveys. In a separate procedure, we also surveyed 17 attendees at a meeting on THOP management held at the 2001 Annual Pediatric Academic Societies meeting. The results of that survey are also reported below, separate from the mail survey.
RESULTS
Of the 62 respondents, 18 (29.0%) indicated that they had treated infants with THOP with thyroid hormone on at least one occasion, and 13 had treated an average of 4.5 infants in the previous 12 months. The mean age at which treatment began (n=14) was 25 days. The level of total thyroxine used to initiate treatment was reported only by 8 neonatologists (average 4.0 g/dl; range 2 to 6). Three respondents indicated that they used free thyroxine as a guide to treatment. Of the 17 neonatologists surveyed at SPR, 7 (41.2%) had treated THOP with thyroid hormone, 6 (35.3%) in the past year, initiating treatment at 13.1 days of age on average.
We mailed a survey on treatment practices for transient hypothyroxinemia of prematurity ( THOP ) to 100 randomly selected neonatologists. In the year before the survey, 13 of 62 respondents ( 21.0% ) had treated an average of 4.5 THOP patients with thyroid hormone, and 3 had treated 10 or more patients. Randomized trials assessing the value of thyroid supplementation in THOP are urgently needed. Original Article
All treating neonatologists had consulted an endocrinologist for advice in managing THOP, and none reported using T 3 .
DISCUSSION
Our survey suggests that a substantial number of neonatologists, nearly a third of those surveyed, have used thyroid hormone to treat infants with THOP, and 20% of them appear to do so with some regularity. At the same time, two-thirds of neonatologists leave THOP wholly untreated (presumably due to lack of consensus as to what are ''pathologic values''). Treatment seems to have been initiated earlier, and provided more frequently, by neonatologists presumably more interested in the problem of THOP, as indicated by the findings in the smaller survey of neonatologists attending a meeting on the subject at the annual meeting of the Pediatric Academic Societies. The division of opinion in neonatal circles indicates that optimum management of THOP is currently unresolved. The study was not designed, though, to collect data regarding the specific type of practice of the responder, nor whether any specific type of practice (e.g., academic, community hospital) influenced therapeutic approach.
Randomized trials have been undertaken to examine the effect of treatment of THOP (Table 1) , but in aggregate, they fail to provide clear answers to this treatment dilemma. All published trials are flawed by small sample sizes, less than ideal treatment schedules, or uncertainty about randomization. Whereas one early trial found a reduction in mortality with T 4 and T 3 supplementation 8 (later development was not assessed), no long-term benefit of T 4 treatment was seen in trials by Chowdry et al. 9 or Vanhole et al. 10 Both latter trials, were, however, very small (12 and 34 subjects, respectively). The largest trial, studied 100 infants <30 weeks, but did not restrict treatment to infants with THOP. 11 Although no significant overall change in neurodevelopment was found, intriguing suggestions of benefit, as well as of potential harm, were identified. Mortality and abnormal neurologic findings were reduced by a third or more in the treatment arm, but numbers were too small for significance. A significant improvement of 18 points in Bayley mental scores at age 18 months was found in infants <27 weeks, but at the same time, a 10-point deficit was seen in infants >28 weeks. Overall, IQ was slightly higher in the placebo group.
In spite of compelling evidence that infants with THOP are more likely to develop neurodevelopmental abnormalities, current treatment guidelines do not recommend thyroid supplementation for infants with low thyroxine levels but normal TSH levels. 12 This position is eminently reasonable in the absence of firm evidence of improvement in outcomes in treated THOP babies. However, the current variation in neonatal practice suggests that it is important to undertake a randomized controlled trial of thyroid supplementation in THOP with enough power to assess whether such treatment can reduce the risk of later neurodevelopmental disabilities. 
